Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a Phase ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...